NCT01085266终止3 期
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 362
研究概览
简要总结
An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Successful completion of 26 weeks of blinded treatment in the HORIZON study
排除标准
- •Any other medical illness or unstable medical condition that may interfere with their ability to comply with study procedures and abide by study restrictions, or may interfere with the ability to interpret safety information.
研究组 & 干预措施
Dimebon (latrepirdine)
Experimental
Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
干预措施: Dimebon (latrepirdine) (Drug)
研究者
相似试验
进行中（未招募）
不适用
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHuntington diseaseMedDRA version: 12.1Level: LLTClassification code 10020469Term: Huntington's choreaEUCTR2009-018123-32-SEMedivation, Inc350
已完成
3 期
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington DiseaseNL-OMON34299Medivation Inc.10
进行中（未招募）
不适用
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusMedDRA version: 12.1Level: LLTClassification code 10020469Term: Huntington's choreaHuntington diseaseEUCTR2009-018123-32-NLMedivation, Inc350
进行中（未招募）
不适用
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHuntington diseaseMedDRA version: 12.1Level: LLTClassification code 10020469Term: Huntington's choreaEUCTR2009-018123-32-DEMedivation, Inc350
进行中（未招募）
不适用
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) - Horizon-PlusHuntington`s CoreaMedDRA version: 9.1Level: LLTClassification code 10020469EUCTR2009-018123-32-ITMEDIVATION, INC.350